Exelixis

ISIN US30161Q1040

WKN 936718

Market cap (in EUR)

10,613 m

Country

United States

Sector

Healthcare

Dividend yield

0.00%

Overview

Quote

Description

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Show more Show less

Healthcare Biopharmaceuticals Non-System-Specific Biopharmaceuticals United States

Chart

Financials

Key metrics

Market capitalisation, EUR	10,613 m
EPS, EUR	2.15
P/B ratio	5.8
P/E ratio	19.6
Dividend yield	0.00%

Income statement (2024)

Revenue, EUR	2,005 m
Net income, EUR	482 m
Profit margin	24.04%

What ETF is Exelixis in?

There are 6 ETFs which contain Exelixis. All of these ETFs are listed in the table below. The ETF with the largest weighting of Exelixis is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).

ETF	Weight	Investment focus	Fund size (in m EUR)
Invesco Global Enhanced Equity UCITS ETF EUR PfHdg Acc	0.07%	Equity World Multi-Factor Strategy	0
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)	0.90%	Equity United States Health Care Biotech	44
Vanguard ESG Global All Cap UCITS ETF (USD) Distributing	0.01%	Equity World Social/Environmental	485
Vanguard ESG North America All Cap UCITS ETF (USD) Distributing	0.02%	Equity North America Social/Environmental	27
Invesco Global Enhanced Equity UCITS ETF Acc	0.07%	Equity World Multi-Factor Strategy	266
JPMorgan BetaBuilders US Small Cap Equity UCITS ETF USD (dist)	0.16%	Equity United States Small Cap	178

Performance

Returns overview

YTD	+21.14%
1 month	+7.04%
3 months	+17.36%
6 months	+5.36%
1 year	+22.91%
3 years	+165.90%
5 years	+135.78%
Since inception (MAX)	+95.36%
2024	+50.00%
2023	+50.07%
2022	-13.33%
2021	+0.78%

Monthly returns in a heat map

Risk

Risk metrics in this section:

Volatility, annualised, measured for 1, 3 and 5 year periods. The annualised volatility reflects the degree of price fluctuations during a one year period. The higher the volatility, the more significantly the price of the asset (stock, ETF, etc.) has changed in the past. Assets with higher volatility are generally considered more risky. We calculate the volatility based on the data for the past 1, 3 and 5 years so that you can see if price fluctuations for the ETF became stronger or weaker over time.
Return per risk for 1, 3 and 5 year periods. This is the annualised (i.e. converted to a one year period) past return divided by the past annualised volatility. The metric puts the historical return of an asset in relation to its historical risk and gives you a retrospective indication of the degree of price fluctuation you had to bear with in order to obtain the return. We calculate this parameter for 1, 3 and 5 year periods to display its evolution over time.
Maximum drawdown for a period. This shows the worst possible loss an investor could have suffered during the respective period, by first buying and subsequently selling the asset at the least favourable prices. For example, if there was the following sequence of daily ETF prices: 10€, 5€, 12€, 20€, an investor would have suffered the worst loss by buying for 10€ and subsequently selling for 5€. Therefore in this case the maximum drawdown would be (5€ - 10€)/10€ = -50%.

ETF returns include dividend payments (if applicable).